ABVC BIOPHARMA INC (ABVC) Stock Price & Overview
NASDAQ:ABVC • US00091F3047
Current stock price
The current stock price of ABVC is 1.09 USD. Today ABVC is up by 0.93%. In the past month the price decreased by -22.69%. In the past year, price increased by 46.9%.
ABVC Key Statistics
- Market Cap
- 27.73M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.26
- Dividend Yield
- N/A
ABVC Stock Performance
ABVC Stock Chart
ABVC Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ABVC. When comparing the yearly performance of all stocks, ABVC is a bad performer in the overall market: 69.87% of all stocks are doing better.
ABVC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ABVC. Both the profitability and financial health of ABVC have multiple concerns.
ABVC Earnings
ABVC Forecast & Estimates
ABVC Groups
Sector & Classification
ABVC Financial Highlights
Over the last trailing twelve months ABVC reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS increased by 73.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.16% | ||
| ROE | -40.73% | ||
| Debt/Equity | 0.07 |
ABVC Ownership
ABVC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ABVC
Company Profile
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 19 full-time employees. The company went IPO on 2004-11-09. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The firm is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. The company has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. The company also focuses on the development of new drugs and medical devices derived from plants.
Company Info
IPO: 2004-11-09
ABVC BIOPHARMA INC
44370 Old Warm Springs Blvd
Fremont CALIFORNIA US
CEO: Howard Doong
Employees: 19
Phone: 15106680881
ABVC BIOPHARMA INC / ABVC FAQ
What does ABVC BIOPHARMA INC do?
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 19 full-time employees. The company went IPO on 2004-11-09. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The firm is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. The company has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. The company also focuses on the development of new drugs and medical devices derived from plants.
Can you provide the latest stock price for ABVC BIOPHARMA INC?
The current stock price of ABVC is 1.09 USD. The price increased by 0.93% in the last trading session.
What is the dividend status of ABVC BIOPHARMA INC?
ABVC does not pay a dividend.
What is the ChartMill technical and fundamental rating of ABVC stock?
ABVC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of ABVC BIOPHARMA INC (ABVC) based on its PE ratio?
ABVC BIOPHARMA INC (ABVC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
What is ABVC BIOPHARMA INC worth?
ABVC BIOPHARMA INC (ABVC) has a market capitalization of 27.73M USD. This makes ABVC a Nano Cap stock.